Targeting the Most Common Cancer Causing Virus
Seventy nine million Americans are infected with HPV. This leads to approximately 270,000 new cases of HPV positive cervical pre-cancers each year. In addition, oral HPV infection has become the main risk factor for head and neck cancers both in men and women. Currently, there is no medication available to treat cancer causing HPV infections. Innovene is developing a new class of therapeutics derived from GRAS compounds (GRAS = Generally Recognized as Safe, as designated by the FDA). TriCurin is the leading therapeutic, preclinical work is complete. The IND application is in progress for a future phase I clinical trial in women with chronic HPV infection.